Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
long term is a great company to own at the right valuation of course which is where it’s at right now. The moat is more resliant and durable compared to traditional human pharma companies. the companion segment will be a growth driver for year to come especially with OA.
0
FAQ
What is Zoetis stock price today?▼
The current price of ZTS is $75.15 USD — it has increased by +0.47% in the past 24 hours. Watch Zoetis stock price performance more closely on the chart.
What is Zoetis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zoetis stocks are traded under the ticker ZTS.
Is Zoetis stock price growing?▼
ZTS stock has risen by +2.59% compared to the previous week, the month change is a -5.4% fall, over the last year Zoetis has showed a -53.34% decrease.
What is Zoetis market cap?▼
Today Zoetis has the market capitalization of 31.5B
When is the next Zoetis earnings date?▼
Zoetis is going to release the next earnings report on August 06, 2026.
What were Zoetis earnings last quarter?▼
ZTS earnings for the last quarter are 1.53 USD per share, whereas the estimation was 1.6 USD resulting in a -4.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Zoetis revenue for the last year?▼
Zoetis revenue for the last year amounts to 9.47B USD.
What is Zoetis net income for the last year?▼
ZTS net income for the last year is 2.67B USD.
Does Zoetis pay dividends?▼
Yes, ZTS dividends are paid quarterly. The last dividend per share was 0.53 USD. As of today, Dividend Yield (FWD)% is 2.83%.
How many employees does Zoetis have?▼
As of July 06, 2026, the company has 13,800 employees.
In which sector is Zoetis located?▼
Zoetis operates in the Health & Wellness sector.
When did Zoetis complete a stock split?▼
Zoetis has not had any recent stock splits.
Where is Zoetis headquartered?▼
Zoetis is headquartered in Parsippany, United States.